Antisense Therapeutics Limited
ATHJF
Price:
$0.012
Market Cap:
$52.29M
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Th...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2009-09-08
Stock Exchange
PNK
Ticker
ATHJF
PE Ratio
[-1.20]
ROE
[-73.14%]
Current Ratio
[4.51]
Dividend Yield
[0%]
Enterprise Value
[41.46M]
Dividend History
The ROE as of December 2024 (TTM) for Antisense Therapeutics Limited (ATHJF) is -73.14%
According to Antisense Therapeutics Limited’s latest financial reports and current stock price. The company's current ROE is -73.14%. This represents a change of 210.99% compared to the average of -23.52% of the last 4 quarters.
Antisense Therapeutics Limited (ATHJF) Historical ROE (quarterly & annually)
How has ATHJF ROE performed in the past?
The mean historical ROE of Antisense Therapeutics Limited over the last ten years is -88.78%. The current -73.14% ROE has changed -17.61% with respect to the historical average. Over the past ten years (40 quarters), ATHJF's ROE was at its highest in in the December 2014 quarter at 7.73%. The ROE was at its lowest in in the December 2017 quarter at -62.32%.
Average
-88.78%
Median
-98.07%
Minimum
-148.63%
Maximum
9.97%
Antisense Therapeutics Limited (ATHJF) ROE by Quarter and Year
Discovering the peaks and valleys of Antisense Therapeutics Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 313.39%
Maximum Annual ROE = 9.97%
Minimum Annual Increase = -651.09%
Minimum Annual ROE = -148.63%
| Year | ROE | Change |
|---|---|---|
| 2023 | -114.08% | 313.39% |
| 2022 | -27.60% | -80.41% |
| 2021 | -140.85% | 8.35% |
| 2020 | -130.00% | 58.40% |
| 2019 | -82.07% | 48.62% |
| 2018 | -55.22% | -62.85% |
| 2017 | -148.63% | 170.56% |
| 2016 | -54.93% | -651.09% |
| 2015 | 9.97% | -106.90% |
| 2014 | -144.39% | 173.33% |
Antisense Therapeutics Limited (ATHJF) Average ROE
How has ATHJF ROE performed in the past?
The current ROE of Antisense Therapeutics Limited (ATHJF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-94.17%
5-year avg
-98.92%
10-year avg
-88.78%
Antisense Therapeutics Limited (ATHJF) ROE vs. Peers
How is ATHJF’s ROE compared to its peers?
Antisense Therapeutics Limited’s ROE is less than Amexdrug Corporation (4.42%), less than Aion Therapeutic Inc. (264.20%), less than Aspen Pharmacare Holdings Limited (9.48%), greater than Alterola Biotech, Inc. (-20.20%), greater than The BC Bud Corporation (-383.06%), greater than Crescita Therapeutics Inc. (-15.60%), greater than AusCann Group Holdings Ltd (-91.60%), greater than Avicanna Inc. (-2164.81%), less than Bionoid Pharma Inc. (33.29%),
| Company | ROE | Market cap |
|---|---|---|
| 4.42% | $338.82K | |
| 264.20% | $1.98M | |
| 9.48% | $5.44B | |
| -20.20% | $4.38M | |
| -383.06% | $4.81M | |
| -15.60% | $8.58M | |
| -91.60% | $1.67M | |
| -2164.81% | $24.80M | |
| 33.29% | $10.19M |
Build a custom stock screener for Antisense Therapeutics Limited (ATHJF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Antisense Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Antisense Therapeutics Limited (ATHJF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Antisense Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Antisense Therapeutics Limited's ROE?
How is the ROE calculated for Antisense Therapeutics Limited (ATHJF)?
What is the highest ROE for Antisense Therapeutics Limited (ATHJF)?
What is the 3-year average ROE for Antisense Therapeutics Limited (ATHJF)?
What is the 5-year average ROE for Antisense Therapeutics Limited (ATHJF)?
How does the current ROE for Antisense Therapeutics Limited (ATHJF) compare to its historical average?